Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm

Boston Scientific launched the AVANT GUARD trial in 2023 to assess FARAPULSE PFA System's efficacy as a primary treatment for persistent atrial fibrillation.